Lyell Immunopharma Inc (LYEL)
2.615
+0.08
(+2.95%)
USD |
NASDAQ |
May 15, 16:00
2.615
0.00 (0.00%)
After-Hours: 16:06
Lyell Immunopharma Cash from Investing (Quarterly): 21.99M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 21.99M |
| December 31, 2023 | -100.69M |
| September 30, 2023 | 99.67M |
| June 30, 2023 | 152.91M |
| March 31, 2023 | 32.15M |
| December 31, 2022 | 46.65M |
| September 30, 2022 | -57.08M |
| June 30, 2022 | 25.02M |
| March 31, 2022 | -26.12M |
| Date | Value |
|---|---|
| December 31, 2021 | -73.86M |
| September 30, 2021 | -144.91M |
| June 30, 2021 | -39.47M |
| March 31, 2021 | 136.68M |
| December 31, 2020 | 32.39M |
| September 30, 2020 | -89.94M |
| June 30, 2020 | -99.88M |
| March 31, 2020 | -116.08M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-144.91M
Minimum
Sep 2021
152.91M
Maximum
Jun 2023
-11.80M
Average
-26.12M
Median
Mar 2022
Cash from Investing (Quarterly) Benchmarks
| GlycoMimetics Inc | -0.0074M |
| Candel Therapeutics Inc | -0.027M |
| Eliem Therapeutics Inc | 36.75M |
| Entrada Therapeutics Inc | 26.15M |
| NovaBay Pharmaceuticals Inc | 1.068M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -42.02M |
| Cash from Financing (Quarterly) | 0.027M |
| Free Cash Flow | -160.68M |
| Free Cash Flow Per Share (Quarterly) | -0.1654 |
| Free Cash Flow to Equity (Quarterly) | -42.05M |
| Free Cash Flow Yield | -24.37% |